SORAFENIB

Generic	Brand	HICL	GCN	Exception/Other
SORAFENIB TOSYLATE	NEXAVAR	33400		

This drug requires a written request for prior authorization.

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC)?

   If yes, **approve for 12 months by HICL with a quantity limit of #4 tablets per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of unresectable hepatocellular carcinoma?

   If yes, **approve for 12 months by HICL with a quantity limit of #4 tablets per day.**
   If no, continue to #3.

3. Does the patient have a diagnosis of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment?

   If yes, **approve for 12 months by HICL with a quantity limit of #4 tablets per day.**
   If no, do not approve.
   DENIAL TEXT: Approval requires a diagnosis of advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinoma, or locally recurrent/metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

RATIONALE
Ensure appropriate utilization of sorafenib based on FDA approved indication and NCCN guidelines.

FDA APPROVED INDICATION
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma and locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

CONTINUED ON NEXT PAGE

STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

SORAFENIB

REFERENCES

- Bayer HealthCare Pharmaceuticals Inc. Nexavar package insert. Wayne, NJ. November 2013.
- National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. (Version 1.2011).
- National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. (Version 2.2011).

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 04/01/14
Created: 05/11
Client Approval: 03/14
P&T Approval: 02/14